Key Highlights
- Acadia Pharmaceuticals (NASDAQ:ACAD) rose 10.79% on November 10, 2026, one of the session's strongest gains on a day when the S&P 500 fell 0.38%.
- The move followed oral argument at the US Court of Appeals for the Federal Circuit over the Patent covering the 34 mg capsule formulation of Nuplazid.
- If the patent is upheld, Nuplazid is protected until February 2038; if not, protection runs to October 2030 under its compound patent and paediatric exclusivity.
- A ruling is expected in the first half of 2027, and the company will also present remlifanserin data at a medical meeting on November 17.
What Drove the Move
Late on November 9, Acadia Pharmaceuticals (NASDAQ:ACAD) commented on the oral argument held in the appeal by generic drugmakers against a May 2025 district court judgment that upheld its formulation patent for Nuplazid, the only approved treatment for hallucinations and delusions linked to Parkinson's disease psychosis. Investors appear to have read the hearing as favourable to the company, and shares jumped 10.79% the next day. The stakes are large. Nuplazid is a major part of company revenue, and the difference between protection running to 2030 and to 2038 is several extra years of branded sales without generic competition. The company was careful to note that the court has set no timeline for its decision, which it expects in the first half of 2027, so the jump reflects a reassessment of the odds rather than a final outcome. Judges' questions at oral argument are an imperfect guide to rulings, and appeals courts can reverse or send back lower court decisions.
The Business Behind the Stock
Acadia reported third-quarter 2026 Revenue of USD 342 million, up 22% from a year earlier, driven by both Nuplazid and Daybue, its treatment for Rett syndrome. The company raised its Daybue sales guidance to USD 505 million to USD 520 million and set total revenue guidance at USD 1.265 billion to USD 1.295 billion. Those figures show a business with two growing commercial products and enough Cash Flow to fund its pipeline. One headwind is policy: Nuplazid is expected to face a negotiated price under the Inflation Reduction Act from 2029, which will reduce its revenue in Medicare even before any generic entry. That makes the length of patent protection after 2029 slightly less valuable than it would otherwise be, but still significant for long-term forecasts and for the value placed on the shares. Because so much of the long-term valuation depends on how long Nuplazid stays exclusive, even a modest change in perceived patent risk can move the shares sharply.
What to Watch Next
The next catalyst arrives quickly. On November 17, the company will present data from the Phase 2 portion of the RADIANT study of remlifanserin, testing 60 mg and 30 mg once-daily doses against placebo, at a major Alzheimer's disease conference in Boston. Remlifanserin is aimed at psychosis in Alzheimer's disease, a much larger population than Parkinson's disease psychosis, and positive data would add a third growth leg. For Acadia Pharmaceuticals (NASDAQ:ACAD), the patent ruling, Daybue growth outside the US and remlifanserin progress are the three issues that will drive the valuation through 2027. A positive remlifanserin readout would shift attention from defending existing revenue to building new growth, while a weak result would put more weight on the patent outcome.
Where Things Stand
Acadia rose 10.79% on November 10, 2026 after the appeals court heard arguments over the Nuplazid formulation patent, which would protect the drug until 2038 if upheld. The ruling is expected in the first half of 2027. Meanwhile, revenue grew 22% in the third quarter and remlifanserin data arrive on November 17, giving investors several catalysts in the months ahead.






Please wait processing your request...